Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $54,168.69 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $87.51, for a total transaction of $54,168.69. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,503,375.34. This represents a 1.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Up 0.2%

Shares of Edwards Lifesciences stock opened at $84.54 on Monday. The stock has a market capitalization of $48.68 billion, a P/E ratio of 48.59, a price-to-earnings-growth ratio of 2.21 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The company has a 50-day simple moving average of $89.16 and a 200 day simple moving average of $85.81. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently added to or reduced their stakes in the company. Tidal Investments LLC raised its holdings in Edwards Lifesciences by 2.1% during the 2nd quarter. Tidal Investments LLC now owns 104,368 shares of the medical research company’s stock worth $9,441,000 after purchasing an additional 2,159 shares during the last quarter. Van Hulzen Asset Management LLC grew its position in shares of Edwards Lifesciences by 4.3% during the 2nd quarter. Van Hulzen Asset Management LLC now owns 35,500 shares of the medical research company’s stock worth $3,211,000 after buying an additional 1,476 shares during the period. National Pension Service raised its stake in shares of Edwards Lifesciences by 0.7% during the second quarter. National Pension Service now owns 998,775 shares of the medical research company’s stock worth $90,349,000 after buying an additional 7,009 shares during the last quarter. Cidel Asset Management Inc. bought a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $227,000. Finally, Plimoth Trust Co. LLC acquired a new position in Edwards Lifesciences in the second quarter valued at approximately $206,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Truist Financial lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. BTIG Research restated a “buy” rating and set a $110.00 target price on shares of Edwards Lifesciences in a report on Friday. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Finally, Mizuho upped their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.